HER2-Targeted Antibody-Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget's Disease Models: In Vivo and Immunohistochemical Analyses.

Tokuchi, Keiko; Maeda, Takuya; Kitamura, Shinya; Yanagi, Teruki; Ujiie, Hideyuki

Tokuchi, Keiko; Maeda, Takuya; Kitamura, Shinya; Yanagi, Teruki; Ujiie, Hideyuki.

Afiliación

Tokuchi K; Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
Maeda T; Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
Kitamura S; Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
Yanagi T; Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
Ujiie H; Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.

Cancers (Basel) ; 14(14)2022 Jul 20.

Article en En | MEDLINE | ID: mdl-35884581

Palabras clave

ERBB2; HER2; antibodydrug conjugate; extramammary Paget's disease; patient-derived xenograft

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google